A New Class of
Synthetic Anti-Infectives
About
Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.
Proprietary new class of anti-infectives against bacteria and viruses
Designed to work against antibiotic-resistant bacteria
Multiple clinical indications and formulations in Phase I,
II including a registrational Phase III trial in Indonesia, addressing unmet medical needs
A Universal Mechanism of Action
Recce’s New Class of Synthetic Anti-Infectives have a universal mechanism of action with the ability to overcome hyper-cellular mutation of bacteria and viruses. Recce’s anti-infectives are unique – their potency does not diminish even with repeated use, a common failure associated with existing drugs.
Recce continues to strengthen and expand its product pipeline of therapeutic options for ‘difficult to treat’ bacterial infections – including their mutated forms.
